Immunoassay for LMP1 in nasopharyngeal tissue based on surface-enhanced Raman scattering.
Immunoassay for LMP1 in nasopharyngeal tissue based on surface-enhanced Raman scattering.
复制标题
基于表面增强拉曼散射的鼻咽组织中LMP1的免疫分析
DOI：
10.2147/ijn.s26854
复制
发表时间：
2012
影响因子：
8
通讯作者：
Zeng H
中科院分区：
文献类型：
--
作者：
Chen Y;Zheng X;Chen G;He C;Zhu W;Feng S;Xi G;Chen R;Lan F;Zeng H
已有研究表明，EB病毒（Epstein-Barr virus，EBV）编码的潜伏膜蛋白1（latent membrane protein 1，LMP 1）与鼻咽癌的发生、发展密切相关，可作为鼻咽癌筛查的肿瘤标志物。在这里，我们报告了一种新的方法，高度特异性和敏感的表面增强拉曼散射（Sers）技术的基础上检测LMP 1鼻咽组织切片直接与传统的免疫组化方法不需要繁琐的程序。首先制备了LMP 1功能化的4-巯基苯甲酸（4-MBA）标记的Au/Ag核-壳纳米粒子，然后将其用于分析来自34名癌症患者和20名健康对照的福尔马林固定石蜡包埋的鼻咽组织切片中的LMP 1。从每个组织切片上的25 × 25点正方形区域获取Sers光谱，并用于生成Sers图像。Sers光谱和图像数据表明，这种新的基于SERS的免疫检测法检测LMP 1在福尔马林固定的石蜡包埋鼻咽组织切片具有高灵敏度和特异性。新的LMP 1-Sers探针方法的结果是上级优于那些传统的免疫组化染色LMP 1，并在与那些在原位杂交EB病毒编码的小RNA（EBER）的协议。这种新的Sers技术有可能发展成为一种新的临床工具，用于鼻咽癌的检测和鉴别诊断，以及预测鼻咽癌的转移和免疫靶向治疗。
Previous studies have shown that Epstein–Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) is closely associated with the occurrence and development of nasopharyngeal carcinoma, and can be used as a tumor marker in screening for the disease. Here we report a new methodology based on highly specific and sensitive surface-enhanced Raman scattering (SERS) technology to detect LMP1 in nasopharyngeal tissue sections directly with no need of tedious procedures as with conventional immunohistochemistry methods. LMP1-functionalized 4-mercaptobenzoic acid (4-MBA)-labeled Au/Ag core-shell bimetallic nanoparticles were prepared first and then applied for analyzing LMP1 in formalin-fixed paraffin-embedded nasopharyngeal tissue sections obtained from 34 cancer patients and 20 healthy controls. SERS spectra were acquired from a 25 × 25 spot square area on each tissue section and used to generate SERS images. Data from SERS spectra and images show that this new SERS-based immunoassay detected LMP1 in formalin-fixed paraffin-embedded nasopharyngeal tissue sections with high sensitivity and specificity. The results from the new LMP1-SERS probe method are superior to those of conventional immunohistochemistry staining for LMP1, and in excellent agreement with those of in situ hybridization for EBV-encoded small RNA (EBER). This new SERS technique has the potential to be developed into a new clinical tool for detection and differential diagnosis of nasopharyngeal carcinoma as well as for predicting metastasis and immune-targeted treatment of nasopharyngeal carcinoma.